> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# Northwest Bio Waits on London While Its Cash Runs Thin
- URL: https://www.pennystocks.news/northwest-bio-cash/
- Published: 2026-11-18T19:56:29.000Z
- Updated: 2026-11-18T19:56:29.000Z
- Description: The MHRA decides whether DCVax-L gets approved. The balance sheet decides how many shares those holding today will be sharing it with.
- Author: PennyStocksNews Team
- Tags: NWBO, OTC

Almost three years after Northwest Biotherapeutics asked the UK regulator to approve its brain cancer vaccine DCVax-L, its quarterly report says the same thing it has said for months: the application "is in the process of undergoing MHRA review".

No decision date. No hearing date. And the company that is waiting ended September with **$725,000 in cash**.

## The balance sheet

Against that cash, Northwest Bio reported total liabilities of **$122.4 million**. It lost $28.8 million in the third quarter alone and $41.1 million over nine months.

The stock traded at $0.149 on Wednesday afternoon, up 2.0% on the day.

The filing says there is substantial doubt about the company's ability to continue as a going concern.

## How the bills get paid

Mostly with shares. In the first nine months of the year, Northwest Bio issued about **189 million shares** to settle and convert debt. Shares outstanding reached 1.81 billion on 10 November, out of 2.6 billion authorised.

On 26 October it took another loan from Streeterville Capital: $5.505 million at 8% interest, with a 10% original issue discount. Repayments start in June 2027, at 110% of each principal instalment. In other words, the company receives less than the face amount and pays back more.

## What the board is arguing about

The NWBO board splits the usual way. Longs say approval is close and the loans are a bridge to it. Shorts point to the cash line and the share count.

The filing gives neither side a date. What it gives is a timeline measured in loans: each new note buys time, and each conversion adds shares that dilute whatever an approval would be worth.

**The MHRA decides whether DCVax-L gets approved. The balance sheet decides how many shares those holding today will be sharing it with.**